Phaseline

Companies › Inimmune

Inimmune: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INI-4001
TLR7/8 agonist
TLR7, TLR8Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06302426INI-4001Phase 1Advanced Solid TumorOncologyJun 2026

Targets

TLR7 (1) TLR8 (1)

Companies with the same targets

Merck KGaA Eikon Therapeutics United Immunity Beeline Medicines HighField Biopharmaceuticals Ascendis Pharma Oncology Division Bolt Biotherapeutics OX2 Therapeutics Primmune Therapeutics Solstice Oncology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.